EYLEA® 8mg

EYLEA® 8mg (114.3 mg/ml) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).

 

What value would your patients place on an opportunity to minimize burden of treatment?

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.

What would extending intervals mean for patients like Joseph?

What would extending intervals mean for patients like Joseph?

Discover more on the nAMD page 

LEARN MORE
What would it mean for patients like Jasmin to visit the clinic less often than is currently expected?

What would it mean for patients like Jasmin to visit the clinic less often than is currently expected?

Discover more on the DME page

LEARN MORE

    DME, diabetic macular edema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q16, every 16 weeks. Q20, every 20 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.

PP-EYL_8mg-IL-0025-1

    • 1
      EYLEA® 8mg SmPC as approved by the Israeli MoH.